Save $$$ on Risperdal purchased online

Alkermes, Inc. (NASDAQ: ALKS) today announced positive preclinical
results for three proprietary molecules targeting opioid receptors,
including ALKS 33. Data from two preclinical studies demonstrated that
the three molecules showed statistically superior oral efficacy as
well as evidence for improved metabolic and pharmacokinetic profiles
compared to an active control. The data were presented at the 2008
Research Society on Alcoholism/International Soc…